Vintafolide: Completed Phase IIb enrollment

Endocyte disclosed in its 2Q13 earnings that it completed enrollment in the open-label, international Phase IIb TARGET trial comparing 2.5 mg vintafolide given on days 1, 4, 8 and 11 as a single agent and in combination with docetaxel vs. docetaxel alone in about 180 patients. The trial enrolled patients whose target lesions all express the folate receptor as determined by the companion imaging diagnostic etarfolatide ( EC20) from Endocyte. ...